BEYONTTRA

This brand name is authorized in France, Lithuania.

Active ingredients

The drug BEYONTTRA contains one active pharmaceutical ingredient (API):

1	Acoramidis UNII T12B44A1OE - ACORAMIDIS
	Transthyretin amyloid cardiomyopathy is initiated by the dissociation of the transthyretin (TTR) tetramer into its constituent monomers. Acoramidis is a specific stabiliser of TTR. Acoramidis was designed to mimic the disease protective genetic variant (T119M), through the formation of hydrogen bonds with adjacent serine residues within both thyroxine binding sites of the tetramer.
	Read more about Acoramidis

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BEYONTTRA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01EB25		C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations
Discover more medicines within C01EB25

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	62404505
LT	Valstybinė vaistų kontrolės tarnyba	1102700